Humulin N (Insulin Human (Rdna))

Humulin N is a recombinant DNA insulin human product supplied for subcutaneous injection, available in multiple strengths. It is a prescription‑only intermediate‑acting insulin indicated for the management of blood glucose in adults and children with type 1 or type 2 diabetes mellitus. Marketed in the European Union, Humulin N provides a predictable basal insulin profile to help maintain glycaemic control once daily, stored refrigerated until use.

Humulin N is used as part of a comprehensive diabetes management plan to provide basal insulin coverage.

- Control fasting plasma glucose levels in patients with type 1 diabetes. - Maintain basal insulin requirements in adults with type 2 diabetes who need supplemental insulin. - Combine with rapid‑acting insulin analogues for a basal‑bolus regimen. - Adjust dosing during periods of illness, stress, or changes in physical activity. - Facilitate transition from other intermediate‑acting insulins when appropriate. - Provide basal insulin support in pediatric patients with type 1 diabetes when a stable glucose profile is required.

Like all insulin preparations, Humulin N may be associated with adverse reactions that vary in frequency and severity.

Common: - Hypoglycemia, presenting as sweating, tremor, hunger, or confusion. - Injection site reactions such as redness, swelling, or itching. - Lipodystrophy, including localized lipoatrophy or lipohypertrophy. - Weight gain due to increased glucose storage.

Serious: - Severe hypoglycemia leading to loss of consciousness or seizures. - Allergic reactions ranging from urticaria to anaphylaxis. - Edema or fluid retention, potentially worsening heart failure. - Hypersensitivity with fever, chills, or systemic symptoms.

When prescribing Humulin N, clinicians should consider several precautionary measures to ensure safe and effective use.

- Assess renal and hepatic function, as impairment may alter insulin clearance. - Educate patients on recognizing and treating hypoglycemia promptly. - Adjust doses during pregnancy, lactation, or in the elderly due to variable insulin sensitivity. - Avoid use in patients with known hypersensitivity to recombinant human insulin. - Monitor for signs of lipodystrophy and rotate injection sites regularly. - Consider cardiovascular status, as fluid retention can exacerbate heart failure. - Review concomitant medications that may mask hypoglycemia symptoms.

Humulin N can interact with other agents, affecting glucose control or insulin action.

Avoid: - Concurrent use of other intermediate‑acting insulins without dose adjustment. - Combination with high‑dose sulfonylureas, which may precipitate severe hypoglycemia. - Co‑administration with glucagon antagonists that blunt counter‑regulatory responses.

Use with caution: - Beta‑blockers may mask hypoglycemia symptoms; monitor glucose closely. - Corticosteroids can increase insulin resistance, requiring dose escalation. - Thiazide diuretics may raise blood glucose levels. - Alcohol intake can cause delayed hypoglycemia; advise moderation.